Why the study?
CYP2C19 genotype influences clopidogrel bioactivation, with intermediate and poor metabolizers facing reduced platelet inhibition and elevated cardiovascular risk, prompting an updated clinical guideline.
Does CYP2C19 genotype-guided antiplatelet therapy improve outcomes in patients receiving clopidogrel?
Design
Clinical practice guideline update
Loading...
Guides CYP2C19 testing to optimize clopidogrel therapy; extends 2013 CPIC recommendations with updated evidence.
Does CYP2C19 genotype-guided antiplatelet therapy improve outcomes in patients receiving clopidogrel?
This 2022 CPIC guideline update expands indications and strengthens recommendations for CYP2C19 genotype-guided antiplatelet therapy, particularly for intermediate metabolizers.
A 2022 study conducted a review in Patients receiving clopidogrel therapy. CYP2C19 genotype-guided antiplatelet therapy was evaluated. The 2022 CPIC guideline update expands indications for CYP2C19 genotype-guided antiplatelet therapy and increases the strength of recommendation for CYP2C19 intermediate metabolizers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: